Method. The study was designed as retrospective, and vimentin, Ki67, and CD44 expressions were evaluated by immunohistochemistry in 53 pancreatic ductal adenocarcinoma cases. This evidence concerns the gene VIM and pancreatic ductal adenocarcinoma.